515814-01-4

Product Details:

CasNo： 515814-01-4

Molecular Formula： C63H111N11O12

Appearance： White to off-white Solid

Delivery Time： 2 weeks after order

Throughput： 100KG/Month

Purity： 99%

Synonyms: Isatx 247; Isatx247; Isatx-247; Luveniq; Lx211; R 1524
Boiling point: 1303.8±65.0 °C
Density: 1.016±0.06 g/cm3
Solubility: Benzene (Slightly), Methanol (Slightly)
Pka: 13.32±0.70

Description:
Voclosporin, a structurally similar analogue of cyclosporin A, is a new type of calcineurin inhibitor. It has been modified to increase its activity by 3-4 times and exhibits a dual and synergistic mechanism. This drug works by blocking the expression of IL-2 and T cell-mediated immune response, stabilizing renal podocytes. Compared to cyclosporin, voclosporin has the advantage of having less impact on cholesterol and triglycerides and a lower risk of diabetes. In February 2021, vorcyclosporine was approved by the FDA for use in combination immunosuppressive regimens in adult patients with active, lupus nephritis.

Uses:
A new agent for the treatment of noninfectious uveitis. Uveitis is an inflammatory, putative Th1-mediated autoimmune disease that affects various parts of the eye and is a leading cause of visual loss. Voclosporin, a rationally designed novel calcineurin inhibitor, exhibits a favorable safety profile, a strong correlation between pharmacokinetic and pharmacodynamic response, and a wide therapeutic window. Immunosuppressant.

Definition:
Voclosporin is a homodetic cyclic peptide. It is a semi-synthetic calcineurin (CN) inhibitor that exhibits potent immunosuppressive activity.